Organization
The Ohio State University College of Medicine
17 abstracts
Abstract
Approaches to engaging participants in a national cancer genomics research network.Org: The Ohio State University College of Medicine, University of New Mexico Comprehensive Cancer Center, University of Colorado School of Medicine,
Abstract
Persistent poverty impacts survival and National Comprehensive Cancer Network guideline-concordant care for patients with melanoma.Org: The Ohio State University College of Medicine, The Ohio State University Wexner Medical Center, The Ohio State University James Cancer Center,
Abstract
The impacts of area-level social deprivation on overall survival in patients receiving immune-checkpoint inhibitors (ICI) treatments: A retrospective cohort study.Org: The Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center, Department of Biomedical Informatics, The Ohio State University College of Medicine,
Abstract
Health equity in multi-cancer early detection (MCEDs): A literature review and content analysis.Org: Department of General Internal Medicine, The Ohio State University College of Medicine, The Ohio State University - James Cancer Hospital,
Abstract
Association between post-CART terminal complement complex (TCC) levels and clinically significant immune effector cell–associated neurotoxicity syndrome (ICANS).Org: The Ohio State University College of Medicine, The Ohio State University - Division of Hematology, Medical College of Wisconsin, Division of Hematology, The Ohio State University,
Abstract
Predictors of poor response to immune-checkpoint inhibitor (ICI) treatment among patient with hepatocellular carcinoma (HCC).Org: The Ohio State University Wexner Medical Center, Columbus, OH, The Ohio State University College of Medicine, The Ohio State University Wexner Medical Center and Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,
Abstract
Predictors of good outcomes in patients with hepatocellular carcinoma (HCC) treated with transarterial radioembolization (TARE).Org: The Ohio State University Wexner Medical Center, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,
Abstract
Novel STK11 differentiation phenotype classifier STK11-DPC: Immunosuppressive tumor microenvironment (TME) and response to immune checkpoint blockade (ICB) in STK11-deficient NSCLC.Org: The James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Ohio State University Comprehensive Canvcer Hospital, The Ohio State University - James Cancer Hospital, The Ohio State University Wexner Medical Center,
Abstract
Factors associated with severe immune checkpoint inhibitor-induced pneumonitis.Org: The Ohio State University - James Cancer Hospital, The Ohio State University - Biostatistics Department, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,
Abstract
Impact of obesity on the risk of immune-related adverse events (irAEs) among patients receiving immune-checkpoint inhibitors (ICI) treatment: A retrospective cohort study.Org: The Ohio State University College of Medicine, Ohio State University Comprehensive Cancer Center, Department of Biomedical Informatics, The Ohio State University, The Ohio State University - James Cancer Hospital,
Abstract
Hospitalization for immune related toxicity and overall survival (OS) among patients with metastatic non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab.Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Ohio State University Comprehensive Canvcer Hospital, Center for Biostatistics and Department of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University Wexner Medical Center and Comprehensive Cancer Center,
Abstract
Comparative assessment of manual chart review and patient-level adverse drug event identification using artificial intelligence in evaluating immunotherapy‑related adverse events (irAEs).Org: The Ohio State University - James Cancer Hospital, Department of Biomedical Informatics, The Ohio State University, The Ohio State University College of Medicine, Ohio State University Wexner Medical Center,
Abstract
Sex differences in prognostic utility of peripheral eosinophil count in first-line immune checkpoint therapy against metastatic NSCLC.Org: Ohio State University Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University College of Medicine, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, The Ohio State University Wexner Medical Center,
Abstract
Predictors of response in advanced colorectal cancer (CRC) patients treated with immune-checkpoint inhibitors (ICI).Org: The Ohio State University College of Medicine, Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, Wexner Medical Center and The James Cancer Hospital, Ohio State University,
Abstract
Risk factors (RF) for poor outcomes in esophageal (EC) and gastric (GC) adenocarcinomas treated with immune-checkpoint inhibitors (ICI).Org: The Ohio State University College of Medicine, Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, Wexner Medical Center and The James Cancer Hospital, Ohio State University,
Abstract
Patterns of weight change and overall survival (OS) during first-line pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC).Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, James Cancer Hospital & Solove Research Institute, Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University College of Medicine, Ohio State University Wexner Medical Center,
Abstract
Real-world experience and outcomes of immune-checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC).Org: Ohio State University Comprehensive Canvcer Hospital, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, The Ohio State University Wexner Medical Center, Ohio State University Wexner Medical Center,